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Title:	Online	4D	ultrasound	guidance	for	real‐time	motion	compensation	by	MLC	50	
tracking	
By‐line:	Online	4D	ultrasound‐guided	MLC	tracking	
Purpose:	 With	 the	 trend	 in	 radiotherapy	 moving	 towards	 dose	 escalation	 and	 hypofractionation,	 the	 need	 for	 highly	
accurate	 targeting	 increases.	While	MLC	tracking	 is	already	being	successfully	used	 for	motion	compensation	of	moving	
targets	in	the	prostate,	current	real‐time	target	localization	methods	rely	on	repeated	x‐ray	imaging	and	implanted	fiducial	55	
markers	or	electromagnetic	transponders	rather	than	direct	target	visualization.	In	contrast,	ultrasound	imaging	can	yield	
volumetric	data	 in	real‐time	(3D	+	time	=	4D)	without	 ionizing	radiation.	We	report	the	 first	results	of	combining	these	
promising	techniques	–	online	4D	ultrasound	guidance	and	MLC	tracking	–	in	a	phantom.	
Methods:	A	 software	 framework	 for	 real‐time	 target	 localization	was	 installed	directly	on	a	4D	ultrasound	 station	and	
used	to	detect	a	2	mm	spherical	lead	marker	inside	a	water	tank.	The	lead	marker	was	rigidly	attached	to	a	motion	stage	60	
programmed	to	reproduce	nine	characteristic	 tumor	 trajectories	chosen	 from	 large	databases	 (five	prostate,	 four	 lung).	
The	 3D	marker	 position	 detected	 by	 ultrasound	was	 transferred	 to	 a	 computer	 program	 for	MLC	 tracking	 at	 a	 rate	 of	
21.3	Hz	and	used	for	real‐time	MLC	aperture	adaption	on	a	conventional	linear	accelerator.	The	tracking	system	latency	
was	measured	using	sinusoidal	trajectories	and	compensated	for	by	applying	a	kernel	density	prediction	algorithm	for	the	
lung	traces.	To	measure	geometric	accuracy,	static	anterior	and	lateral	conformal	fields	as	well	as	a	358°	arc	with	a	10	cm	65	
circular	aperture	were	delivered	for	each	trajectory.	The	two‐dimensional	(2D)	geometric	tracking	error	was	measured	as	
the	difference	between	marker	position	and	MLC	aperture	center	in	continuously	acquired	portal	images.	For	dosimetric	
evaluation,	VMAT	treatment	plans	with	high	and	low	modulation	were	delivered	to	a	biplanar	diode	array	dosimeter	using	
the	same	trajectories.	Dose	measurements	with	and	without	MLC	tracking	were	compared	to	a	static	reference	dose	using	
3%/3	mm	and	2%/2	mm	γ‐tests.	70	
Results:	 	The	overall	 tracking	system	latency	was	172	ms.	The	mean	2D	root‐mean‐square	 tracking	error	was	1.03	mm	
(0.80	mm	prostate,	1.31	mm	lung).	MLC	tracking	improved	the	dose	delivery	in	all	cases	with	an	overall	reduction	in	the	γ‐
failure	rate	of	91.2%	(3%/3	mm)	and	89.9%	(2%/2	mm)	compared	to	no	motion	compensation.	Low	modulation	VMAT	
plans	had	no	(3%/3	mm)	or	minimal	(2%/2	mm)	residual	γ‐failures	while	tracking	reduced	the	γ‐failure	rate	from	17.4%	
to	2.8%	(3%/3	mm)	and	from	33.9%	to	6.5%	(2%/2	mm)	for	plans	with	high	modulation. 	75	
	3	
	
Conclusions:	Real‐time	4D	ultrasound	 tracking	was	 successfully	 integrated	with	online	MLC	 tracking	 for	 the	 first	 time.	
The	developed	framework	showed	an	accuracy	and	latency	comparable	with	other	MLC	tracking	methods	while	holding	
the	potential	to	measure	and	adapt	to	target	motion,	including	rotation	and	deformation,	non‐invasively.	
	
1. INTRODUCTION	80	
The	fundamental	goal	of	radiation	therapy	is	to	maximize	the	dose	to	the	treatment	target	while	minimizing	the	dose	to	
the	 surrounding	 healthy	 tissue.	 Technological	 advancements	 such	 as	 volumetric	 arc	 therapy	 (VMAT)	 or	 stereotactic	
ablative	body	radiotherapy	(SABR)	have	led	to	improved	dose	distributions	with	steeper	gradients	and	better	sparing	of	
organs‐at‐risk.	 Due	 to	 the	 current	 trend	 towards	 dose	 escalation	 and	 hypofractionation,	 the	 need	 for	 highly	 accurate	
targeting	increases.	This	is	especially	challenging	for	organs	and	structures	affected	by	motion.1	Uncompensated	motion	85	
can	 lead	 to	 a	 substantial	 loss	 of	 target	 coverage	 and	 dose	 smearing,	 impairing	 treatment	 quality.2–4	 As	 a	 consequence,	
intra‐fractional	 motion	 compensation	 is	 a	 field	 of	 active	 research	 consisting	 of	 two	 major	 aspects:	 real‐time	 target	
localization	and	treatment	adaptation.	
Adaptation	 of	 the	 treatment	 beam	 can	 be	 achieved	 by	 gating	 or	 tracking	 methods.	 While	 gating	 can	 be	
implemented	 on	most	 clinical	 linear	 accelerators,	 it	 can	 prolong	 treatment	 time	 considerably	 and	 is	mainly	 suited	 for	90	
periodic	motion.	Active	beam	 steering,	 i.e.	 tracking,	 ideally	 does	not	 add	 treatment	 time	and	 is	 currently	 commercially	
available	in	the	robotic	CyberKnife	system	(Accuray,	Sunnyvale,	CA)5	and	the	Vero	gimbal	system	(BrainLab,	Germany	and	
Mitsubishi	 Heavy	 Industries,	 Japan)6.	 	 These	 systems	 are	 highly	 specialized	 and	 complex	 and	 therefore	 not	 nearly	 as	
common	 as	 conventional	 gantry‐based	 accelerators.	 In	 an	 effort	 to	 integrate	 tracking	 into	 clinical	 routine,	 Keall	 et	 al.	
introduced	MLC	tracking	in	2001.3	It	was	successfully	used	for	prostate	tracking	in	a	first	clinical	trial	in	20137	and	for	lung	95	
SBRT	at	the	end	of	2015.8	After	being	clinically	demonstrated,	MLC	tracking	is	likely	to	become	commercially	available	in	
the	future	and	move	towards	widespread	clinical	utilization.	MLC	tracking	has	the	unique	potential	to	account	not	only	for	
rigid	target	shifts	but	also	for	rotational	motion	and	target	deformations.9		
The	current	standard	for	real‐time	target	localization	is	the	use	of	external	or	internal	surrogate	markers.	External	
markers	monitored	with	infrared	cameras can provide	a	superficial	breathing	curve	which	is	assumed	to	be	correlated	to	100	
the	internal	target	motion.	In	the	CyberKnife	system,	this	method	is	extended	with	internal	position	data.	Metal	fiducials	
are	 implanted	 close	 to	 the	 target,	 imaged	with	 kV‐imagers	 and	 correlated	 to	 the	 external	 breathing	 curve,	 providing	 a	
more	accurate	correlation	model.10	However,	the	model‐based	approach	is	prone	to	“unexpected”	motion	that	was	not	part	
of	 the	model‐building	process	and	aperiodic	 shifts.	A	 localization	 technique	 fully	based	on	 internal	markers	 is	available	
with	 the	 Calypso	 system	 (Varian	 Medical	 Systems,	 Palo	 Alto,	 CA),	 where	 electromagnetic	 transponders	 are	 implanted	105	
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around	the	target	and	continuously	monitored	by	external	antennas	at	25	Hz.11		All	of	the	aforementioned	methods	share	
the	 common	 drawback	 of	 relying	 on	 surrogate	 signals,	 thus	 not	measuring	 the	 actual	 target	 position.	 A	 high	 tracking	
accuracy	requires	the	invasive	implantation	of	markers	and,	in	the	case	of	the	CyberKnife	and	the	Vero	gimbal	system,	also	
additional	imaging	dose	to	the	patient.		
Imaging	modalities	such	as	magnetic	resonance	imaging	(MRI)	or	ultrasound	might	solve	these	problems	as	they	110	
provide	superior	soft	tissue	contrast	compared	to	x‐ray‐based	methods	and	a	high	temporal	resolution.	MRI‐guidance	is	
being	thoroughly	investigated	with	one	commercial	system	on	the	market12	and	several	research	groups	working	on	the	
integration	of	MRI	into	a	radiotherapy	setup13–15.	It	provides	volumetric	images	with	highest	anatomical	quality,	however	
at	the	cost	of	a	much	higher	system	complexity	and	much	lower	temporal	resolution.16		
In	contrast,	modern	ultrasound	systems	can	visualize	entire	volumes	 in	real‐time	with	high	 frame	rates.	 In	 this	115	
paper,	 we	 define	 the	 term	 “4D”	 as	 time‐resolved,	 three‐dimensional	 volumes	 acquired	 (and	 visualized)	 in	 real‐time.	
Different	 methods	 for	 target	 localization	 in	 4D	 ultrasound	 are	 currently	 under	 investigation.	 Registration‐based	
approaches	can	yield	an	accuracy	below	2	mm	and	account	for	deformation	but	at	the	cost	of	high	computation	times	in	
the	 range	of	 seconds	 to	minutes	prohibiting	 real‐time	motion	 compensation.17–19	Harris	et	al.	 demonstrated	4D	 speckle	
tracking	 in	 a	 phantom	using	 a	mechanical	 sweeping	 probe	with	 an	 acquisition	 frequency	 of	 1‐2	Hz	 and	 sub‐millimeter	120	
accuracy.20,	 21	Yet,	 Lediju‐Bell	et	al.	 showed	 in	2012	 that	 a	minimum	sampling	 rate	of	4‐12	Hz	 is	 required	 to	accurately	
measure	respiratory	or	cardiac	motion.22		
Despite	showing	promising	results,	all	of	 these	studies	were	performed	offline	on	previously	acquired	data	and	
have	not	been	tested	in	a	realistic	tracking	scenario.	To	the	best	of	our	knowledge,	only	one	group	has	reported	on	online	
ultrasound	tracking	of	respiratory	motion.	Schwaab	et	al.	used	a	pseudo‐3D	ultrasound	transducer	with	two	perpendicular	125	
2D	planes	to	measure	target	motion	and	actively	steer	a	proton	beam.23	With	a	total	system	latency	of	about	200	ms	they	
reported	an	accuracy	of	4.8	mm	in	a	phantom	when	compared	to	PET	imaging.24		
In	 this	 study,	we	 describe	 the	world‐first	 online	 4D	 ultrasound‐guided	MLC	 tracking	 experiment	with	 a	 direct	
communication	link	between	the	ultrasound	system	and	the	MLC	controller	of	a	linear	accelerator.	By	combining	two	of	
the	most	promising	techniques	for	treatment	adaptation	and	target	localization	we	hope	to	demonstrate	the	feasibility	of	130	
using	 ultrasound	 for	 intra‐fractional	 motion	 compensation	 with	 widespread	 usability	 in	 conventional	 radiotherapy	
systems.		
	
2. MATERIALS	AND	METHODS	
2.1 Tracking	system	135	
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The	tracking	system	as	illustrated	in	Figure	1	consists	of	two	major	components:	(1)	A	commercially	available	ultrasound	
station	modified	for	online	tracking	and	data	streaming	and	(2)	an	MLC	tracking	prototype	system	integrated	with	a	linear	
accelerator.	Data	transfer	between	both	systems	was	realized	via	UDP	network	communication.			
Online	4D	ultrasound	target	localization	was	performed	on	a	Vivid	7	dimension	(General	Electrics,	Fairfield,	CT)	
with	 a	 cardiovascular	 3V	matrix	 array	 probe	 using	 the	 second	 harmonic	 2.0/4.0	MHz	mode.	 To	 be	 able	 to	 record	 and	140	
process	 the	 volumetric	 data,	 a	 special	 client/server	 framework	 was	 designed	 allowing	 the	 installation	 of	 custom	
applications	directly	on	the	ultrasound	station.	This	is	crucial	to	circumvent	the	bottleneck	of	data	transfer	via	network,	
which	can	cause	delays	of	up	to	100	ms	(data	size	~1	MB	per	volume).		
For	target	localization,	a	maximum	intensity	search	was	used	to	find	a	phantom	marker	in	an	ultrasound	volume.	
After	a	cluster	of	bright	voxels	was	located	within	the	volume,	the	neighboring	area	was	interpolated	using	splines	and	the	145	
resulting	marker	position	was	found	at	the	maximum	value	of	the	interpolated	space.	For	more	complex	targets,	e.g.	soft‐
tissue	tumors,	template	matching	was	also	implemented	although	not	used	in	this	study.	Template	matching	calculates	the	
squared	 difference	 between	 the	 observed	 volume	 and	 a	 previously	 captured	 patient‐specific	 template.	 The	 maximum	
similarity	 (minimum	 difference)	 over	 all	 positions	 indicates	 the	 target	 location.	 In	 our	 experiments,	 we	 chose	 the	
maximum	intensity	search	since	it	detects	a	spherical	marker	in	a	water	tank	with	the	highest	possible	accuracy	 in	 less	150	
than	 5	ms.	 Template	matching	would	 be	 used	 in	 real	 anatomical	 data	with	more	 scattering	 structures	 to	 track,	 adding	
about	15	ms	computation	time.	The	target	position	was	sent	from	the	ultrasound	station	to	the	MLC	tracking	computer	in	
real‐time	via	UDP	messages.	
MLC	 tracking	 experiments	 were	 conducted	 on	 a	 Trilogy	 linear	 accelerator	 with	 a	 120	 leaf	 Millennium	 MLC	
equipped	with	a	PortalVision	IAS500	portal	imager	(Varian	Medical	Systems,	Palo	Alto,	CA).		155	
	6	
	
	
Figure	1:	Workflow	of	ultrasound‐guided	MLC	tracking	using	an	ultrasound	station	modified	for	online	image	processing	and	data	transfer	
and	a	prototype	MLC	tracking	system	for	real‐time	leaf	optimization.	
	
2.2 Experimental	setup	160	
As	shown	in	Figure	2,	the	ultrasound	phantom	consisted	of	a	water	bath	with	damping	material	opposite	to	the	ultrasound	
transducer	to	avoid	acoustical	 interference	artefacts	and	a	spherical	 lead	marker	(Ø	2	mm)	attached	to	a	plastic	pointer.	
The	phantom	was	placed	on	the	treatment	couch	with	the	transducer	pressed	against	one	side	using	a	tripod	and	coupling	
gel.	The	ultrasound	station	calculated	distances	based	on	the	assumed	mean	speed	of	sound	in	soft	tissues	(1540	m/s).	To	
avoid	systematic	errors	introduced	by	the	different	speed	of	sound	in	pure	water	(1480	m/s),	the	phantom	was	filled	with	165	
a	6.5%	saline	solution	as	higher	salinity	increases	the	speed	of	sound.25		
	 	
Figure	2:	(a)	Setup	for	geometric	accuracy	assessment	of	online	ultrasound‐guided	MLC‐tracking.	A	lead	sphere	in	a	water	bath	was	moved	
by	a	motion	stage,	detected	with	4D	ultrasound	and	its	position	sent	to	the	MLC	tracking	software	which	calculated	and	updated	the	MLC	
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aperture.	 (b)	Setup	 for	dosimetric	accuracy	assessment	with	a	biplanar	diode	array	 in	 the	 isocenter	and	 the	ultrasound	phantom	at	 the	
inferior	end.	170	
Motion	traces	
The	main	aim	of	 this	 study	was	 to	 investigate	ultrasound‐guided	MLC	 tracking	by	generating	data	 that	are	comparable	
with	current	state‐of‐the‐art	target	localization	methods	such	as	electromagnetic	transponders	or	kV	imaging.	Therefore,	
we	adapted	 the	experimental	 setup	 from	previous	 studies26–28	 and	used	 the	 same	prostate	and	 lung	 tumor	 trajectories,	
carefully	selected	from	large	databases29,	30	in	order	to	cover	a	wide	range	of	motion	types	as	summarized	in	Table	1	(lung	175	
–	“typical”,	high‐frequency,	predominant	left–right,	baseline	variations;	prostate	–	stable,	high‐frequency,	continuous	drift,	
persistent	excursion,	transient	excursion).	More	details	on	the	utilized	traces	can	be	found	in	previous	publications.27,	 31	
Prostate	motion	was	chosen	because	highly	complex	motion	can	occur	in	some	cases	while	lung	tumor	trajectories	show	
especially	 large	 magnitudes	 and	 high	 frequencies	 of	 quasi‐periodic	 motion	 well‐suited	 to	 test	 tracking	 and	 prediction	
performance.		180	
	
Table	1:	Motion	trajectories	used	for	geometric	and	dosimetric	tracking	accuracy	measurements.	
	 Motion	range	(mm)
Region	 Trajectory	 S‐I	 A‐P	 L‐R	
Prostate	 High	frequency 8.3 10.8 1.5
Continuous	drift 8.2 7.5 2.0
Persistent 5.2 8.7 1.1
Stable 1.4 0.8 0.7
Transient 6.0 14.5 1.1
Lung	 Baseline	shift 5.6 17.0 18.1
High	frequency 17.8 2.4 1.2
Predominantly	LR 1.7 7.7 21.4
Typical 11.5 2.5 1.9
	
Latency	and	geometric	accuracy	
Tracking	latency	and	geometric	accuracy	were	measured	using	a	10cm	diameter	circular	field	with	the	MLC	leaves	aligned	185	
in	the	superior‐inferior	(SI)	direction.	A	beam	energy	of	6MV	was	used.	As	shown	in	Figure	2a,	the	pointer	with	the	lead	
sphere	was	mounted	on	a	programmable	motion	stage32	and	submerged	in	the	water	tank.	A	simple	isocenter	alignment	of	
the	sphere	based	on	orthogonal	MV	images	was	performed	in	accordance	with	previous	experiments,	e.g.	by	Ravkilde	et	
al.28	By	moving	the	motion	stage	along	the	main	axes	the	ultrasound	system	was	calibrated	to	transform	the	ultrasound	
coordinates	into	the	treatment	coordinates	of	the	accelerator.	MV	portal	images	showing	the	lead	sphere	and	the	circular	190	
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MLC	aperture	were	 continuously	 acquired	 at	 12.9	Hz	by	 an	AS500	portal	 imager	 (Varian)	during	 the	experiments.	 The	
pixel	size	in	the	isocenter	was	0.44	mm.		
For	latency	estimation,	the	motion	stage	performed	sinusoidal	motions	with	12	mm	peak‐to‐peak	amplitude	and	
period	lengths	of	2	s,	3	s,	4	s,	5	s	and	6	s.	The	latency	of	the	tracking	chain	was	determined	as	the	time	lag	between	the	lead	
sphere	motion	and	the	MLC	aperture	motion	in	portal	image	series	of	2	min	duration	(see	Figure	3).	The	mean	latency	for	195	
the	 five	 period	 lengths	was	 reported.	 Since	 the	 image	 acquisition	 and	 target	 localization	 time	depends	 strongly	 on	 the	
geometry	 of	 the	 imaged	 volume,	 latency	 was	 investigated	 for	 three	 different	 volume	 settings.	 The	 smallest	 volume,	
acquired	using	the	in‐built	zoom	function	of	the	ultrasound	station,	covered	a	depth	of	45	mm	(at	130	mm	target	distance)	
and	8	by	6	degrees	in	the	azimuthal	and	elevational	direction.	This	17	x	14	x	45	mm³	volume	was	updated	at	a	frame	rate	
of	 250	Hz.	 To	 cover	 an	 increasing	 extent	 of	motion,	 a	medium	 and	 large	 volume	with	 30	 by	 22	 degrees	 and	 30	 by	 46	200	
degrees	 (68	mm	x	50	mm	and	68	mm	x	105	mm,	both	measured	at	130	mm	depth)	were	acquired	 covering	170	mm	 in	
depth	with	frame	rates	of	21.3	Hz	and	17.8	Hz,	respectively.	For	the	subsequent	experiments,	the	medium	volume	size	was	
chosen	as	a	good	compromise	between	motion	range,	resolution	and	speed.	
To	measure	geometric	accuracy,	the	motion	stage	was	programmed	with	the	prostate	and	lung	trajectories	(see	
previous	 section).	 For	 each	 trajectory,	 three	 treatment	 fields	 with	 600	MU	 were	 delivered	 with	 600	MU/min:	 static	205	
anterior,	static	lateral	and	a	358°	arc.	For	lung	motion,	a	kernel	density	estimation	algorithm33	was	used	to	account	for	the	
estimated	system	latency.	The	treatment	was	started	20	s	after	the	start	of	ultrasound	tracking	since	the	motion	prediction	
algorithm	needed	a	 training	data	 set	of	measured	3D	ultrasound	positions.	No	 latency	compensation	by	prediction	was	
used	for	the	prostate	cases	due	to	the	irregular	patterns	of	prostate	motion.		
In	an	offline	analysis,	the	lead	sphere	and	the	circular	MLC	aperture	were	segmented	in	each	portal	image.34	The	210	
2D	tracking	error	in	beam’s	eye	view	was	calculated	as	the	difference	between	the	marker	position	and	the	center	of	the	
circular	MLC	aperture	for	each	portal	image.	The	root‐mean‐square	(rms)	of	the	tracking	error	was	determined	for	each	
treatment.		
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Figure	3:	Latency	estimation	by	calculating	the	phase	shift	between	the	sine	functions	fitted	to	the	segmented	position	of	the	target	marker	215	
(blue)	and	the	circular	MLC	aperture	(red)	in	continuous	portal	images.	
	
Dosimetric	accuracy	
A	 dosimeter	 phantom	 (Delta4PT,	 ScandiDos,	 Sweden)	 with	 two	 orthogonal	 planar	 diode	 arrays	 encased	 in	 cylindrical	
PMMA	 was	 mounted	 on	 a	 programmable	 motion	 stage	 (HexaMotion,	 ScandiDos)	 and	 used	 for	 measurements	 of	 the	220	
dosimetric	 accuracy.	 The	 lead	 sphere	 pointer	 was	 rigidly	 attached	 to	 the	 dosimeter	 and	 the	 ultrasound	 phantom	was	
placed	at	the	inferior	end	outside	the	treated	region	(Fig.	2a).	The	ultrasound	system	was	again	realigned	with	treatment	
room	coordinates.		
For	each	trajectory,	VMAT	treatment	plans	with	high	and	low	modulation	were	delivered	once	with	MLC	tracking	
and	 once	 without.	 The	 plans	 were	 the	 same	 as	 used	 in	 the	 study	 by	 Keall	 et	 al.27	 Additionally,	 a	 reference	 dose	 was	225	
delivered	to	a	static	phantom	for	each	of	the	four	plans	(two	prostate,	two	lung).	The	dose	distributions	with	and	without	
MLC	 tracking	were	 compared	with	 the	 static	 dose	using	 γ‐tests	with	3%	and	2%	dose	difference	 and	3	mm	and	2	mm	
distance	to	agreement	(normalized	to	the	static	isocenter	dose	with	a	10%	low	dose	cutoff).	The	fraction	of	points	failing	
the	γ	‐test	(the	γ‐failure	rate)	was	recorded	for	each	plan	and	each	tumor	trajectory.	
	230	
3. RESULTS	
The	mean	(and	standard	deviation)	of	the	tracking	system	latency	for	the	five	sinusoidal	motions	was	184.6	ms	(8	ms)	for	
the	large	volume	size,	172.2	ms	(11	ms)	for	the	medium	volume	and	95.5	ms	(8	ms)	for	the	smallest	tracking	volume.	Since	
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the	subsequent	experiments	were	conducted	with	 the	medium	volume	setting,	 the	prediction	 length	 for	 the	 lung	 traces	
was	set	to	170	ms.		235	
3.1 Geometric	accuracy	
Figure	 4	 shows	 the	 tracking	 results	 for	 two	 prostate	 and	 one	 lung	 tumor	 trajectory	 extracted	 from	portal	 images.	 The	
mean	Cartesian	resolution	of	the	ultrasound	volume	in	the	target	area	(depth	ca.	130	mm)	was	0.3	x	0.8	x	1.6	mm.	The	rms	
errors	for	all	27	experiments	(nine	trajectories,	three	fields)	are	summarized	in	Table	2.	The	overall	tracking	accuracy	was	
1.03	mm	 with	 a	 precision	 (standard	 deviation)	 of	 0.3	mm.	 The	 lung	 traces,	 having	 a	 higher	 motion	 amplitude	 and	240	
frequency,	showed	a	higher	error	of	1.31	mm	compared	with	0.80	mm	for	the	prostate.	Most	prostate	traces	were	tracked	
with	 sub‐millimeter	 accuracy	 (the	 only	 exception	 being	 the	 high‐frequency	 excursion)	 and	 0.1	mm	precision	while	 the	
lung	trajectories	were	tracked	with	sub‐2‐mm	accuracy	and	0.2	mm	precision.	
Visual	 inspection	 of	 the	 tracking	 results	 showed	 a	 constant	 systematic	 offset	 of	 ‐0.4	mm	 in	 the	 SI‐direction	
between	the	marker	position	and	the	MLC	aperture	center	in	all	measurements	(see	Figure	4).	It	lies	in	the	range	of	one	245	
MV	imager	pixel	and	could	have	been	introduced	by	a	misalignment	that	occurred	during	or	after	the	initial	calibration.	
Assuming	that	this	error	could	be	avoided	with	a	more	thorough	calibration	and	a	higher	imager	resolution,	the	offset	was	
manually	subtracted	to	investigate	its	impact	on	the	tracking	results.	After	offset	correction,	the	overall	tracking	error	was	
reduced	to	0.85	mm	(0.61	mm	prostate,	1.16	mm	lung).		
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Table	2:	Mean	tracking	errors	(rms)	of	ultrasound‐guided	MLC	tracking	for	nine	trajectories	and	three	field	types.	A	systematic	offset	was	
observed	in	the	original	measurements	(see	Figure	4)	and	corrected	for	retrospectively	to	assess	its	impact	in	the	right	part	of	the	table.		
	 	 Mean	tracking	error	(mm)
	 	 No	offset	correction With	offset	correction	(‐0.4	mm)	
Region	 Trajectory	 358°Arc	
Static
Lateral
Static
Anterior	
358°
Arc	
Static
Lateral	
Static	
Anterior	
Prostate	 High	frequency	 1.11 1.08 0.78 0.95 0.97 0.59	
Continuous	drift	 0.89 0.87 0.59 0.68 0.69 0.28	
Persistent	 0.82 0.75 0.57 0.73 0.56 0.35	
Stable	 0.97 0.81 0.72 0.75 0.53 0.41	
Transient	 0.73 0.74 0.59 0.74 0.56 0.32	
Mean	±	std	 0.80 ±	0.15 0.61 ±	0.19	
Lung	 Baseline	shift	 1.17 1.12 1.08 1.09 0.99 0.99	
High	frequency	 1.47 1.79 1.61 1.38 1.61 1.47	
Predominantly	LR	 1.03 1.08 1.27 0.92 0.86 1.18	
Typical	 1.48 1.45 1.23 1.24 1.16 1.00	
Mean	±	std	 1.31 ±	0.25 1.16	±	0.24	
All	 Mean	±	std	 1.03 ±	0.35 0.85 ±	0.38	
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Figure	4:	Geometric	tracking	accuracy.	The	tracking	error	was	defined	as	the	rms	difference	between	the	marker	position	(blue)	and	the	
MLC	aperture	center	(red).	A	systematic	offset	was	observed	 in	the	original	measurements	(left)	and	was	corrected	for	retrospectively	by	
manual	 subtraction	 (right).	The	numbers	 specify	 the	mean	2D	 root‐mean‐square	 tracking	error	over	all	 three	 treatment	 fields	 for	each	
trajectory.	
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3.2 Dosimetric	accuracy	
The	motion‐induced	 γ‐failure	 rates	 for	 the	 high‐modulation	VMAT	plans	 are	 shown	 in	 Figure	 5	with	 and	without	MLC	
tracking.	Table	3	and	Table	4	summarize	all	results	of	the	3%/3	mm	and	2%/2	mm	γ‐tests.		
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Figure	5:	Dosimetric	accuracy	of	ultrasound‐guided	MLC	tracking.	The	percentage	of	dose	values	failing	the	3%/3mm	and	2%/2mm	γ‐test,	
with	and	without	tracking,	for	the	high‐modulation	VMAT	plans	and	nine	motion	traces.	Note	that	the	y‐scale	is	different	for	all	four	plots.		
In	 all	 cases,	MLC	 tracking	 improved	 the	 γ‐failure	 rate	 substantially	 compared	with	 the	 results	without	motion	
compensation.	All	low	modulation	plans	had	no	remaining	γ‐failures	above	2%/2	mm	when	tracking	was	applied,	except	
for	the	persistent	excursion	prostate	(0.2%)	and	typical	lung	(0.3%)	traces	in	the	2%/2	mm	test.	Especially	the	persistent	270	
excursion	prostate	trace	seemed	to	be	more	complicated	to	track	than	other	traces	as	it	resulted	in	the	highest	observed	
tracking	 failure	 rates	 of	 9.8%	 (3%/3	mm)	 and	 18.4%	 (2%/2	mm)	 for	 the	 high	 modulation	 plans.	 Without	 motion	
compensation,	 the	 typical	 lung	 trace	 caused	 the	 highest	 dose	 discrepancies	 with	 up	 to	 86%	 (low	 modulation	 plan,	
2%/2	mm	γ‐test).		
For	 the	 high	 and	 low	modulation	 lung	plans	 combined,	 the	 failure	 rate	 in	 the	3%/3	mm	γ‐test	was	 0.3%	with	275	
tracking	compared	with	19.9%	without	tracking	and	1.0%	compared	with	38.0%	in	the	2%/2	mm	test.	For	the	combined	
prostate	plans,	2.3%	and	9.5%	(3%/3	mm)	and	5.1%	and	22.0%	(2%/2	mm)	of	the	dose	points	failed	with	and	without	
tracking,	respectively.	The	overall	improvement	from	plan	delivery	without	motion	compensation	to	real‐time	treatment	
adaptation	was	91.2%	for	the	3%/3	mm	and	89.9%	for	the	2%/2	mm	γ‐test.	Improvements	from	tracking	were	generally	
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higher	 in	 the	 lung	 plans	 compared	 with	 the	 prostate.	 The	 VMAT	 plans	 with	 ultrasound‐guided	 MLC	 tracking	 were	280	
delivered	without	beam	holds	and	completed	in	the	same	time	as	the	static	and	no‐tracking	plans.	
Table	3:	3%	/	3	mm	γ‐failure	rates	for	nine	trajectories	and	two	degrees	of	modulated	VMAT	plans.	
	 	 3%	/	3	mm γ‐failure	rates	in	%	
	 	 High	Modulation Low	Modulation	
Region	 Trajectory	 No	tracking	 MLC	tracking	 No	tracking	 MLC	tracking	
Prostate	 High	frequency	 10.3 3.7 2.8 0.0	
Continuous	drift	 34.1 5.7 21.4 0.0	
Persistent	 17.6 9.8 0.2 0.0	
Stable	 0.7 0.0 0.0 0.0	
Transient	 7.0 3.7 0.8 0.0	
Mean	 13.9 4.6 5.0 0.0	
Lung	 Baseline	shift	 1.3 0.3 0.0 0.0	
High	frequency	 1.8 0.0 3.0 0.0	
Predominantly	LR	 16.1 2.0 1.4 0.0	
Typical	 68.0 0.0 67.5 0.0	
Mean	 21.8 0.6 18.0 0.0	
All	 Mean	 17.4 2.8 10.8 0.0	
	
Table	4:	2%	/	2	mm	γ‐failure	rates	for	nine	trajectories	and	two	degrees	of	modulated	VMAT	plans.	
	 	 2%	/	2	mm γ‐failure	rates	in	%	
	 	 High	Modulation Low	Modulation	
Region	 Trajectory	 No	tracking	 MLC	tracking	 No	tracking	 MLC	tracking	
Prostate	 High	frequency	 28.0 11.3 14.5 0.0	
Continuous	drift	 53.7 11.6 46.3 0.0	
Persistent	 33.0 18.4 6.6 0.2	
Stable	 5.1 0.0 0.8 0.0	
Transient	 25.4 9.4 7.0 0.0	
Mean	 29.0 10.1 15.0 0.0	
Lung	 Baseline	shift	 8.4 1.7 0.0 0.0	
High	frequency	 41.2 0.0 41.6 0.0	
Predominantly	LR	 30.4 5.7 16.8 0.0	
Typical	 80.2 0.3 85.5 0.3	
Mean	 40.1 1.9 36.0 0.1	
All	 Mean	 33.9 6.5 24.3 0.1	
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4. DISCUSSION	
In	 this	 study,	 real‐time	 4D	 ultrasound	 guidance	was	 successfully	 integrated	with	 a	 prototype	MLC	 tracking	 system	 for	
online	motion	 compensation	 for	 the	 first	 time.	By	using	a	 custom	ultrasound	phantom	and	motion	stages	programmed	
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with	 different	 patient	 tumor	 traces,	 the	 system	 was	 characterized	 regarding	 its	 latency,	 geometric	 and	 dosimetric	
accuracy.		290	
The	overall	system	latency	includes	image	acquisition,	target	localization,	transfer,	waiting	time	before	next	leaf	
fitting,	aperture	optimization	and	travel	time	of	the	MLC	leaves.35	As	the	last	two	components	are	more	or	less	constant	
(~56	ms)35,	 the	 latency	 of	 the	 system	 is	 mainly	 determined	 by	 the	 target	 localization	 frequency	 (acquisition	 and	
detection).	 A	 smaller	 volume	 leads	 to	 less	 reconstructed	 ultrasound	 beams	 and	 thus	 a	 faster	 frame	 rate.	 The	 smallest	
tracking	volume	of	17	x	14	x	45	mm³	(at	130	mm	depth)	with	a	 frame	rate	of	250	Hz	 led	to	a	system	latency	of	95.5	ms	295	
which	 is	 the	shortest	 latency	reported	so	 far	 for	MLC	 tracking.	 In	 the	 literature	on	electromagnetic	 transponder‐guided	
MLC	tracking,	values	of	146	ms	for	the	wireless	Calypso	system31	(Varian	Medical	Systems,	Palo	Alto,	CA)	and	140	ms	for	
the	wired	Raypilot28	 (Micropos	Medical	 AB,	 Gothenburg,	 Sweden)	were	 reported.	 Image‐guided	MLC	 tracking	methods	
show	 higher	 latencies	 of	 264	ms	 and	 382	ms	 for	 5	Hz	 kV‐	 and	 MV‐imaging,	 respectively.36	 The	 172	ms	 latency	 of	
ultrasound‐guided	tracking	covering	a	large	volume	is	substantially	lower	than	the	other	image‐guided	methods	and	only	300	
slightly	 higher	 than	 the	 fastest	 reported	methods	with	 electromagnetic	 transponders.	 It	 is	 also	 faster	 than	 the	 2D‐2D‐
ultrasound‐guided	proton	therapy	system	by	Schwaab	et	al.	with	a	reported	latency	of	200	ms.23	
It	 should	be	noted	 that	 the	 image	acquisition	 time	 in	ultrasound	 is	mainly	affected	by	 the	number	of	beams	or	
angles	along	the	up‐down	and	left‐right	directions	within	the	volume	while	the	scan	depth,	i.e.	the	direction	away	from	the	
probe,	has	a	much	smaller	effect	on	the	frame	rate.	Thus,	if	the	probe	was	aligned	with	the	main	motion	axis	of	the	tumor,	305	
e.g.	 superior‐inferior	 for	many	 respiratory	motions,	 the	 volume	 size	 could	 potentially	 be	 reduced	 below	 the	 currently	
chosen	68	mm	x	50	mm	 if	 the	 expected	 residual	 tumor	motion	 is	much	 less.	A	 lower	 latency	 could	 also	 reduce	 latency‐
related	 errors	 which	 tend	 to	 have	 the	 highest	 impact	 when	 tracking	 high‐frequency	 motions,	 requiring	 further	
investigation.26		
While	 the	 acoustic	 mechanisms	 of	 image	 acquisition	 make	 ultrasound	 an	 attractive	 modality	 for	 real‐time,	310	
radiation‐free	 imaging,	 they	 also	 cause	 one	 of	 ultrasound’s	 main	 limitations:	 speed‐of‐sound‐errors.	 The	 ultrasound	
station	 calculates	 distances	 based	 on	 an	 assumed	mean	 speed	 of	 sound	 in	 soft	 tissues	 (1540	m/s),	 but	 different	 tissue	
types	have	different	physical	properties	based	on	their	composition.	Inside	the	body,	this	can	lead	to	distance	errors	of	up	
to	7%,	i.e.	several	millimeters.37	This	can	currently	be	compensated	retrospectively	by	correcting	the	ultrasound	volumes	
via	ground‐truth	density	information	from	CT38,	but	no	online	solution	is	available.	The	extent	of	speed‐of‐sound	errors	in	315	
vivo	during	tracking	still	needs	to	be	determined	and,	if	required,	compensated	for	in	real‐time	for	accurate	absolute	target	
localization	in	ultrasound.	
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The	measured	geometric	accuracy	of	sub‐1‐mm	for	prostate	and	sub‐2‐mm	for	lung	tumor	trajectories	is	well	in	
accordance	with	reported	localization	errors	of	Calypso34	and	image‐based	tracking	methods39,	40	and	only	slightly	inferior	320	
to	 the	 reported	 accuracy	 of	wired	 transponders	 (all	 traces	 sub‐1‐mm).28	 All	 systems	 except	 for	 Calypso	 are	 still	 in	 the	
research	 state	 and	have	not	 been	used	 clinically.	 The	only	 other	 study	 on	 online	 ultrasound	guidance	 for	 radiotherapy	
reported	 a	 geometric	 error	 of	4.8	mm,	however	 including	an	optical	 calibration	of	 the	 system	 to	 compensate	 for	probe	
motion.24	Since	the	main	aim	of	the	current	work	was	to	investigate	the	feasibility	of	integrating	online	ultrasound	target	
localization	 into	 an	 existing	MLC	 tracking	 framework,	 the	 “best‐case	 scenario”	 was	 chosen:	 the	 ultrasound	 probe	was	325	
calibrated	to	the	isocenter	via	the	motion	stage	in	accordance	with	previous	studies27,	31,	39,	41	but	kept	in	a	fixed	position.	
The	phantom	design	was	minimalistic	to	assess	the	highest	achievable	accuracy.	A	static	systematic	offset	of	‐0.4	mm	in	the	
SI‐direction	was	observed	in	the	original	tracking	data.	Subtraction	of	the	offset	further	reduced	the	total	tracking	error	
down	to	0.85	mm.	It	was	likely	caused	by	an	imperfect	alignment	of	the	lead	sphere	with	the	isocenter	or	an	unintended	
and	unnoticed	shift	of	the	sphere	during	ultrasound	calibration.	During	calibration,	the	location	of	the	isocenter	is	fixed	in	330	
the	ultrasound	volume	as	the	tracking	origin	–	an	offset	would	lead	to	a	systematic	error	in	the	subsequent	measurements.		
Assessing	the	geometric	accuracy	of	ultrasound‐guided	MLC	tracking	based	on	MV	portal	images	in	a	phantom	can	
be	considered	an	intermediate	solution	incorporating	not	only	the	accuracy	of	the	ultrasound	target	localization	but	also	
errors	 from	 the	 MLC	 aperture	 fitting,	 the	 tracking	 latency	 and	 the	 prediction	 algorithm	 (lung	 only).	 The	 method	
determines	 the	 geometric	 error	 of	 the	 entire	 tracking	 system	 in	 beam’s	 eye	 view,	 thus	 measuring	 the	 actual	 error	335	
occurring	at	treatment	delivery.	
	
Dosimetric	evaluation	of	ultrasound‐guided	MLC	tracking	yielded	a	90%	improvement	in	dose	discrepancies	from	
treatments	delivered	without	tracking	to	deliveries	with	real‐time	tracking	applied.	Treatment	efficiency	was	not	reduced	
by	tracking.	Over	the	past	years,	several	MLC	tracking	studies	have	used	the	same	treatment	plans	and	trajectories	(except	340	
for	the	stable	prostate	trace).27,	31,	39,	41	Among	these,	only	Poulsen	et	al.	used	kV	images	for	target	localization39	while	the	
other	studies	used	electromagnetic	transponders.	A	dosimetric	comparison	between	the	current	work	and	four	previous	
studies	can	be	found	in	Table	5	(results	of	the	stable	trace	were	removed	in	the	current	study	for	comparability).		
All	previously	conducted	studies	show	similar	and	substantial	dose	improvements	of	85‐95%	when	MLC	tracking	
is	 applied,	 although	 the	pattern	of	 dose	 errors	 are	different	 in	 the	 two	older	 studies27,  39  that	used	 a	 horizontal	 2D	 ion	345	
chamber	 array	 (PTW	 Seven29)	 than	 in	 the	 later	 studies	 that	 used	 a	 biplanar	 diode	 array	 (Delta4PT)	 for	 dose	
measurements.	While	 the	 older	 studies	 had	 highest	 residual	 γ‐failure	 rates	with	 tracking	 for	 the	 lung	 cases,	 the	more	
recent	works	 including	 the	 current	 study	 had	 largest	 errors	 for	 prostate.	 A	 potential	 source	 of	 this	 discrepancy	 is	 the	
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difference	in	the	dosimeter	geometry.	Besides	this,	larger	errors	may	be	expected	for	kV	image‐based	MLC	tracking	due	to	
a	longer	tracking	system	latency	of	290ms27, 39	as	compared	to	140‐172ms	for	the	other	studies.		350	
In	 the	 newer	 studies,	 the	 γ‐failures	 with	 tracking	 were	 higher	 and	 improvements	 were	 lower	 in	 the	 prostate	
compared	with	the	lung	although	the	geometric	tracking	error	was	generally	higher	for	lung	traces.	There	are	two	factors	
contributing	to	these	seemingly	inconsistent	results.	First,	the	geometric	and	dosimetric	measurements	were	performed	in	
two	different	experiments	which	may	include	different	errors	and	are	therefore	not	directly	linked.	Second,	limitations	in	
the	MLC	leaf	fitting	can	be	assumed	to	be	one	of	the	key	contributors	for	the	higher	prostate	failures.	It	has	previously	been	355	
shown	to	be	the	dominant	contributor	to	MLC	tracking	errors	for	prostate	motion.39	If	the	target	moves	orthogonally	to	the	
MLC	leaf	direction,	the	leaf	fitting	cannot	always	be	optimal	due	to	the	finite	leaf	width.	For	slow	erratic	motion,	e.g.	in	the	
prostate,	the	target	may	stay	in	a	position	for	which	the	leaves	cannot	compensate	for	a	relatively	long	time,	thus	leading	
to	systematic	dose	errors	with	an	accumulation	of	erroneous	dose.	For	faster	periodic	trajectories,	the	dose	errors	caused	
by	leaf	fitting	will	tend	to	be	random	and	cancel	out	better.	This	problem	could	potentially	be	overcome	by	the	utilization	360	
of	thinner	MLC	leaves	or	by	aligning	the	MLC	with	the	main	motion	axis	of	the	target	prior	or	even	during	the	treatment.42		
	
Moving	 towards	 a	 clinical	 implementation	 of	 ultrasound‐guided	 MLC	 tracking,	 the	 integration	 of	 an	 external	
tracking	device	and	the	accuracy	of	a	full	system	calibration	will	be	an	integral	part	of	future	experiments	but	may	increase	
the	geometric	error	of	the	tracking	system.	Another	issue	to	be	addressed	is	the	positioning	of	the	ultrasound	probe.	For	365	
this	purpose,	we	have	developed	a	framework	that	calculates	the	expected	image	quality	from	a	planning	CT	to	optimize	
probe	 positions,	 considering	 target	 visibility	 and	 treatment	 beam	 angles.43	 Due	 to	 the	 high	 attenuation	 it	 has	 been	
recommended	to	avoid	beams	intersecting	with	the	probe44,	but	treatment	planning	“around	the	probe”	was	shown	to	be	
feasible	in	the	majority	of	cases.45	
The	construction	of	a	more	realistic	phantom	with	reproducible	deformations	or	the	utilization	of	another	real‐370	
time	tracking	modality	for	evaluation	is	another	important	precursor	for	in	vivo	tracking	experiments.	So	far,	the	accuracy	
of	 our	 real‐time	 tracking	 system	has	not	 been	quantified	 in	 real	 patient	 data.	 The	main	 reason	 for	 that	 is	 the	 lack	 of	 a	
reliable,	continuous	ground	truth.	Manual	delineation	in	ultrasound	volumes,	even	when	performed	by	experts,	has	a	high	
inter‐	 and	 intra‐observer	 variability46	while	 correlation‐based	 techniques	 only	 approximate	 the	 true	 target	 position	 or	
provide	discrete	absolute	positions.	Using	complex	phantom	and	anatomical	data	with	a	concomitant	ground	truth	motion	375	
signal	 will	 also	 facilitate	 the	 development	 and	 evaluation	 of	 novel	 algorithms	 for	 real‐time	 rotation	 and	 deformation	
tracking.	
Even	 though	 these	 initial	 experiments	 have	 been	 limited	 to	moving	 phantoms,	 the	 chosen	 trajectories	 already	
covered	a	wide	range	of	real	patient	motion	types.	Due	to	their	varying	complexity	they	most	likely	lead	to	higher	errors	
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than	would	be	expected	for	typical	prostate	and	lung	tumor	trajectories.28	Especially	the	lung	trajectories	were	chosen	for	380	
their	 complex,	 high‐frequency	 motion	 patterns	 to	 represent	 the	 most	 challenging	 tracking	 scenarios	 with	 the	 highest	
requirement	for	low	latency.	While	imaging	lung	tumors	with	ultrasound	for	real‐time	motion	compensation	will	be	hardly	
possible	due	to	the	large	acoustic	impedance	mismatch	between	the	air‐filled	lungs	and	the	surrounding	soft	tissue,	this	
type	 of	motion	 is	 still	 relevant	 for	 targets	 located	 in	 the	 upper	 abdomen	 close	 to	 the	 diaphragm.	 Suitable	 regions	 for	
ultrasound	tracking	are	for	example	in	the	liver,	the	prostate	and	also	cardiac	targets	for	novel	treatment	approaches	in	385	
radiotherapy.47		
	
By	avoiding	ionizing	radiation	for	imaging,	having	a	very	high	temporal	resolution	and	at	the	same	time	producing	
volumetric	anatomical	images,	ultrasound	has	striking	advantages	over	other	imaging	techniques	used	in	radiotherapy.	In	
addition	 to	 its	 demonstrated	 ability	 to	 track	 three‐dimensional	 translations	 of	 rigid	 target	 structures	 non‐invasively,	 it	390	
holds	 the	 potential	 to	 measure	 target	 rotations	 and	 even	 deformations	 in	 real‐time.	 The	 capability	 of	 detecting	 such	
complex	target	motion	raises	the	demand	for	sophisticated	treatment	planning,	real‐time	beam	adaptation	and	online	re‐
optimization	techniques.	Further	progress	in	these	fields,	higher	computational	power	as	well	as	new	ultrasound	systems	
with	improvements	in	imaging	hardware,	processing	software	and	research	interfaces	will	all	benefit	the	development	of	
more	accurate	target	 localization	techniques	and	pave	the	way	for	the	 integration	of	real‐time	ultrasound	guidance	into	395	
the	radiotherapy	workflow.		
	
Table	5:	Dosimetric	comparison	of	different	studies	on	dynamic	MLC	tracking	utilizing	the	same	trajectories	and	plans	as	the	current	study.	
Study 
details 
Study  Current study Hansen et al.31 Ravkilde et al.41 Poulsen et al.39  Keall et al.27 
Guidance method  Ultrasound  Calypso  Raypilot  kV‐imaging  Calypso 
Accelerator  Trilogy  TrueBeam  Trilogy  Trilogy  Trilogy 
Dosimeter  Delta4PT  Delta4PT  Delta4PT  PTW Seven29  PTW Seven29
Tracking type  None  MLC  None  MLC  None  MLC  None  MLC  None  MLC 
3%/3mm 
γ‐failures 
Lung, high and low  
modulation combined  19.9%  0.3% 20.4%  0.9%  23.6%  0.2%  41.0%  1.8%  34.0% 1.6%
Prostate, combined   11.8%  2.9% 14.2%  3.3%  10.7%  2.2%  19.5%  1.4%  14.0% 1.2%
All combined  15.8%  1.6% 17.3%  2.1%  17.1%  1.2%  30.3%  1.6%  24.0% 1.4%
Improvement from tracking  91%  88%  93%  95%  94% 
2%/2mm 
γ‐failures 
Lung, combined   38.0%  1.0% 41.1%  2.4%  46.2%  1.6%  53.5%  7.8%  58.0% 6.6%
Prostate, combined   26.8%  6.4% 30.4%  8.1%  24.4%  5.8%  33.0%  2.0%  34.0% 5.7%
All combined  32.4%  3.7% 35.7%  5.3%  35.3%  3.7%  43.3%  4.9%  46.0% 6.1%
Improvement from tracking  90%  85%  89%  89%  86% 
	
5. CONCLUSION	400	
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Real‐time,	 online	 4D	 ultrasound	 tracking	 was	 successfully	 integrated	 with	 MLC	 tracking	 on	 a	 conventional	 linear	
accelerator	for	the	first	time.	It	showed	similar	accuracy	and	latency	as	other	tracking	methods	while	holding	the	potential	
to	measure	target	motion	non‐invasively.	Future	efforts	will	be	focused	on	the	non‐invasive	detection	and	compensation	of	
target	 rotation	 and	 deformation	 as	well	 as	 on	 the	 conduction	 of	 in	vivo	 studies	 for	 further	 validation	 of	 the	 developed	
tracking	framework.		405	
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